Mantle-Cell Lymphoma

This is a type of non-Hodgkin lymphoma. It's called 'mantle-cell' because the cancer cells look like they are part of the 'mantle' cells in lymph nodes. It's a type of 'lymphoma' or 'lymphosarcoma'. It's a serious cancer that affects the immune system.

Condition

What people with Mantle-Cell Lymphoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for Mantle-Cell Lymphoma?

NameHow it went

About Mantle-Cell Lymphoma

What It Is

Mantle-cell lymphoma (MCL) is an uncommon type of non-Hodgkin lymphoma, a cancer of the immune system. It starts in B cells, the white blood cells that make antibodies, in a part of the lymph node called the mantle zone. The abnormal cells build up in lymph nodes and often spread to the bone marrow, spleen, blood and digestive tract. It makes up about 5% of non-Hodgkin lymphomas in the United States, is usually diagnosed around age 65 and is more common in men. MCL behaves very differently from one person to the next. About 1 in 5 people have a slow-growing form that lives mainly in the blood, bone marrow or spleen, with only small lymph nodes and few or no symptoms. Most people have a faster-growing form with enlarged lymph nodes in several areas. Symptoms can include painless swollen lymph nodes, tiredness, fevers, drenching night sweats, unexplained weight loss, abdominal fullness or changes in bowel habits. Some people have no symptoms and learn of it from routine blood work or a scan.

Causes & Risk Factors

In most cases, no cause can be identified, and nothing a person did is known to bring it on. Nearly all MCL cells carry the same acquired genetic change: a swap between chromosomes 11 and 14 that makes the cells overproduce cyclin D1, a protein that pushes cells to divide. This change develops in the lymphoma cells during life. It is not inherited and is not passed to children. Older age and male sex are the clearest patterns. As with non-Hodgkin lymphoma generally, a weakened immune system and some infections are linked to higher risk, but no specific lifestyle or environmental trigger has been established for MCL.

How It's Diagnosed

Diagnosis requires a biopsy, usually removal of all or part of an enlarged lymph node, or a sample of bone marrow, blood or a growth found during colonoscopy. A pathologist confirms MCL by finding B cells with a typical pattern of surface markers and excess cyclin D1, or the chromosome 11;14 swap behind it. Because MCL can resemble other slow-growing lymphomas under the microscope, these tests matter for getting the type right. Staging then shows where the lymphoma is. This usually means a PET-CT scan (a combined positron emission tomography and computed tomography scan that shows active lymphoma throughout the body) and blood tests, and sometimes a bone marrow biopsy or colonoscopy. Most people are found to have stage III or IV disease, meaning lymph nodes on both sides of the diaphragm or spread to organs such as the bone marrow. In MCL that stage is common and does not by itself mean treatment will fail. The lymphoma's biology often says more about outlook than the stage. Doctors look at how fast the cells are dividing (a measure called Ki-67, where 30% or higher signals faster growth), whether the cells look large and immature (called blastoid), and whether the TP53 gene, which normally helps stop damaged cells from multiplying, is altered. These features identify higher-risk disease that responds poorly to standard chemotherapy and points toward different treatment.

Treatment Options

Treatment depends on how fast the lymphoma is behaving, its biology, a person's age and overall health, and their preferences. People with the slow-growing form who feel well may not need treatment right away. Instead, they are monitored with regular visits and tests, and treatment starts if the lymphoma grows or causes symptoms. For most people, first treatment combines several medicines. Rituximab is an antibody that targets a marker on B cells. It is often paired with chemotherapy such as bendamustine, or with more intensive combinations for younger, fit people. Bruton tyrosine kinase (BTK) inhibitors are daily pills that block a signal lymphoma cells need to survive. They have become central to MCL care. Acalabrutinib (Calquence) is approved with bendamustine and rituximab as first treatment for people who cannot have a stem cell transplant. Trials have shown that adding a BTK inhibitor to first treatment allows most people to skip an autologous stem cell transplant, which uses their own stored stem cells after high-dose chemotherapy. That transplant was once standard for younger patients. BTK inhibitors can raise the risk of infection, bleeding and an irregular heart rhythm (atrial fibrillation), so people taking them need regular blood counts and should check with their care team before procedures or blood-thinning medicines. Newer, more selective options such as acalabrutinib and zanubrutinib (Brukinsa) cause atrial fibrillation less often than the original drug in this class. After first treatment brings the lymphoma under control, maintenance rituximab given every few months for at least 2 to 3 years is standard, because it keeps remissions going longer. When MCL returns, options include a different BTK inhibitor, such as pirtobrutinib (Jaypirca) after earlier BTK treatment, other combinations, or chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy, such as brexucabtagene autoleucel (Tecartus), reprograms a person's own immune cells to attack the lymphoma. It can produce deep remissions after other treatments stop working. It also requires treatment at a specialized center and close monitoring for serious reactions, including high fevers and confusion. For the highest-risk disease, doctors may combine targeted drugs or consider a donor (allogeneic) stem cell transplant. Clinical trials are a common and reasonable option at any stage.

What to Expect

MCL usually responds well to treatment, and many people reach remission, meaning no lymphoma can be found on scans and tests. For most, though, it eventually returns, so it is generally treated as a long-term condition managed in phases rather than cured with one course. Outlook has improved substantially with newer treatments. People with the slow-growing form often live 15 years or more, and many with the more common form live 8 to 10 years or longer. Higher-risk features shorten that, while many older adults stay in remission for the rest of their lives. Daily life depends on the phase. Chemotherapy and antibody infusions are usually given in cycles over several months and can cause tiredness, low blood counts and a higher chance of infection. BTK inhibitors are taken by mouth every day, often for long periods, with regular visits for blood tests and side-effect checks. During maintenance and monitoring, many people return to work and their usual routines. Before treatment starts, people are tested for hepatitis B and other infections, because some MCL treatments can reactivate an old hepatitis B infection. Many people also take preventive antiviral or antibiotic medicines during treatment. Living with a lymphoma that can come back brings uncertainty, and scan results can be stressful. Treatment at or in consultation with a center experienced in MCL can help with decisions such as whether to wait, which first treatment to use and when to consider cellular therapy. Support groups and lymphoma organizations can help people and families with practical and emotional challenges.

When to Seek Help

See a doctor if you have swollen lymph nodes that last more than a few weeks, unexplained weight loss, drenching night sweats, persistent tiredness, or ongoing abdominal fullness or bowel changes. If you are being monitored without treatment, report any of these as new or worsening symptoms rather than waiting for the next visit. During treatment, call your care team right away for a fever of 100.5°F (38°C) or higher, shaking chills, or other signs of infection such as a new cough, a sore throat or burning with urination. Infections can become serious quickly when treatment has lowered your white blood cells. Also call promptly about unusual bleeding or bruising, or a racing or irregular heartbeat if you take a BTK inhibitor. After CAR T-cell therapy, follow your center's specific instructions for fever, confusion or other new symptoms.

Questions to Ask Your Doctor

  1. 1.Is my mantle-cell lymphoma the slow-growing or the faster-growing type, and do I need treatment now?
  2. 2.What did my biopsy show about Ki-67, blastoid features and TP53, and how do those results change my options?
  3. 3.What are the realistic goals and main trade-offs of the treatment you recommend, and how long would I be on it?
  4. 4.Should I be seen at a center with MCL expertise, or are there clinical trials that fit my situation?
  5. 5.If the lymphoma comes back, what would the next options be, and should we plan for CAR T-cell therapy?

Last reviewed • Oct 2026

Educational content, not medical advice.